Humacyte, Inc. (NASDAQ: HUMA) completed a registered direct offering of 25 million shares of its common stock, generating gross proceeds of $20 million before offering expenses. The transaction closed on March 20 2026 and was led by a new life‑science dedicated investor and a long‑only mutual fund, with Titan Partners serving as placement agent.
The net proceeds will be directed toward accelerating the commercial launch of Symvess in the vascular trauma indication, supporting the filing of a supplemental Biologics License Application for a hemodialysis indication, and covering the upcoming read‑out of Phase 3 results. Additional allocations will fund development of other product candidates in Humacyte’s pipeline and general corporate purposes.
Humacyte’s cash burn has been a persistent challenge. As of September 30 2025, the company reported $19.8 million in cash, cash equivalents, and restricted cash. The prior capital raise in October 2025 yielded $56.5 million in net proceeds, but the company’s negative EBITDA of $97 million over the last twelve months and a net loss of $17.5 million in Q3 2025 (up from $39.2 million in Q3 2024) underscore the need for additional capital to extend its runway.
Symvess received full FDA approval on December 19 2024 for vascular trauma repair when autologous vein grafts are not feasible, and the U.S. commercial launch began in the first quarter of 2025. Sales grew from $100 000 in Q2 2025 to $703 000 in Q3 2025, reflecting increasing hospital approvals and inclusion in the Defense Logistics Agency’s Electronic Catalog.
The company’s hemodialysis program is supported by positive Phase 3 data. The V012 trial, which compares the ATEV to arteriovenous fistulas in female patients, reached its interim analysis threshold in April 2025 and is expected to be read out in the near term. The results will inform a supplemental BLA filing scheduled for the second half of 2026.
Beyond vascular applications, Humacyte is advancing a bioengineered esophagus and a BioVascular Pancreas program in partnership with Pluristyx, positioning the company to diversify its product portfolio and capture new therapeutic markets. The equity raise strengthens Humacyte’s financial foundation, enabling it to pursue these initiatives while maintaining momentum in its core vascular offerings.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.